1-20 of 34
Shun Lu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma

Hong Wu, Xuefeng Leng, Qianshi Liu, Tianqin Mao, Tao Jiang, Yiqiang Liu, Feifei Li, Chenhui Cao, Jun Fan, Liang Chen, Yaqi Chen, Quan Yao, Shun Lu, Renchuan Liang, Lanlin Hu, Mingxin Liu, Yejian Wan, Zhaoshen Li, Jun Peng, Qiyu Luo, Hang Zhou, Jun Yin, Ke Xu, Mei Lan, Xinhao Peng, Haitao Lan, Gang Li, Yongtao Han, Xia Zhang, Zhi-Xiong Jim Xiao, Jinyi Lang, Guihua Wang, Chuan Xu
Journal: Cancer Research
Cancer Res (2023) 83 (18): 3131–3144.
https://doi.org/10.1158/0008-5472.CAN-22-2593
Published: 15 September 2023
View article titled, Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Open the PDF for Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816

Changli Wang, Ke-Neng Chen, Qixun Chen, Lin Wu, Qun Wang, Xiaofei Li, Kejing Ying, Wenxiang Wang, Jian Zhao, Lunxu Liu, Junke Fu, Chunfang Zhang, Jichun Liu, Yi Hu, Mark M. Awad, Ives Ntambwe, Junliang Cai, Judith Bushong, Phuong Tran, Shun Lu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT081.
https://doi.org/10.1158/1538-7445.AM2023-CT081
Published: 14 April 2023
View article titled, Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816
Journal Articles

Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients

Shun Lu, Qiming Wang, Lin Wu, Ligang Xing, Yintao Li, Liang Han, Xiaorong Dong, Hongying Wei, Wen Xu, Chuan Li, Liuqing Yang, Qiong Wu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT201.
https://doi.org/10.1158/1538-7445.AM2023-CT201
Published: 14 April 2023
View article titled, Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients
Journal Articles

Abstract CT204: Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study

Shun Lu, Hong Jian, Wei Hong, Zhengbo Song, Nong Yang, Sheng Hu, Zibin Liang, Yongsheng Wang, Yan Wang, Min Peng, Yan Yu, You Li, Jiapeng Shuang, Kaijing Zhao
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT204.
https://doi.org/10.1158/1538-7445.AM2023-CT204
Published: 14 April 2023
View article titled, Abstract CT204: Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced <em>HER2</em>-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study
Journal Articles

Abstract LB289: Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies

Shun Lu, Jie Wang, Meili Sun, Jun Zhao, Chunhong Hu, Mengzhao Wang, Jianying Zhou, Yong Song, Qinghua Zhou, Jiayuan Zhang, Yang Shi, Ruiqi Huang, Xikun Wu, Wanyu He, Xiaofei Qu, Yun Zhang, Zhirong Shen, Yan Yu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB289.
https://doi.org/10.1158/1538-7445.AM2023-LB289
Published: 14 April 2023
View article titled, Abstract LB289: Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Journal Articles

Abstract CT214: Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified (MET Amp), c-Met protein overexpressing (c-Met OE), non-squamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY

D. Ross Camidge, Jonathan Goldman, Athan Vasilopoulos, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Elysa Noon, Shun Lu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT214.
https://doi.org/10.1158/1538-7445.AM2023-CT214
Published: 14 April 2023
View article titled, Abstract CT214: Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in <em>MET</em> gene amplified (<em>MET</em> Amp), c-Met protein overexpressing (c-Met OE), non-squamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY
Journal Articles

Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation

Daniel Tan, Koichi Goto, Herbert HF Loong, Tsung-Ying Yang, Shirish Gadgeel, Erminia Massarelli, Gennaro Daniele, Xiuning Le, Yuki Shinno, Haruyasu Murakami, Tomohiro Sakamoto, Jose C. Ruffinelli, Shun Lu, Yiping Zhang, Tae Min Kim, Barbara J. Brennan, Chunlin Chen, Miranda Joosten, Zebin Wang, Su-Fen Pu, Weichao Bao, Martin Kornacker, Roberta Ferraldeschi, Paolo Grassi, Boon Cher Goh
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT126.
https://doi.org/10.1158/1538-7445.AM2023-CT126
Published: 14 April 2023
View article titled, Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
Journal Articles

Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS

Shun Lu, Chuan Li, Hong Jian, Xiaorong Dong, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Jiawei Wei, Si Sun, Zhenzhong Su, Qiu Sun, Hongying Wei, Qiong Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5462.
https://doi.org/10.1158/1538-7445.AM2023-5462
Published: 04 April 2023
View article titled, Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS
Journal Articles

Abstract 5537: MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis

Wenxiang Ji, Shun Lu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5537.
https://doi.org/10.1158/1538-7445.AM2022-5537
Published: 15 June 2022
View article titled, Abstract 5537: MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis
Journal Articles

Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor

Alexander Drilon, Jun Zhong, Ying Lu, Yongbo Liu, Hao Wang, Minchun Chen, Xiaohu Chen, John Zhu, Shun Lu, Vivek Subbiah
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5363.
https://doi.org/10.1158/1538-7445.AM2022-5363
Published: 15 June 2022
View article titled, Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor
Journal Articles

Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)

Shun Lu, Meili Sun, Yunpeng Liu, Yanping Hu, Yanyan Xie, Zhehai Wang, Dong Wang, Zhenzhou Yang, Liang Liang, Yi Huo, Yun Zhang, Ruiqi Huang, Yang Shi, Zhirong Shen, Yan Yu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB512.
https://doi.org/10.1158/1538-7445.AM2022-LB512
Published: 15 June 2022
View article titled, Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
Journal Articles

Abstract CT538: Tepotinib + gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT

Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jianying Zhou, Dong-Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Rolf Bruns, Andreas Johne, Yi-Long Wu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT538.
https://doi.org/10.1158/1538-7445.AM2022-CT538
Published: 15 June 2022
View article titled, Abstract CT538: Tepotinib + gefitinib in patients with <em>EGFR</em>-mutant NSCLC with <em>MET</em> amplification: Final analysis of INSIGHT
Journal Articles

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

Shun Lu, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, Tanaka Kentaro, Lin Wu, Xuhong Min, Wei Zhang, Dingzhi Huang, Yongqian Shu, Chengzhi Zhou, Min Li, Xiaorong Dong, Chong Bai, Lu Li, Jiuwei Cui, Li Zhang, Lejie Cao, Xiaoling Li, AiMin Zang, Haruki Kobayashi, Yiping Zhang, Yan Yu, Xiuwen Wang, Terufumi Kato, Shoichiro Yamamoto, Yuki Shinno, Xiaoyan Lin, Yanqiu Zhao, Yanping Hu, Qitao Yu, Ziping Wang, Masahiro Kodani, Jian Fang, Jialei Wang, Meiqi Shi, Diansheng Zhong, Wen Dong, Hiroshi Tanaka, Yasuto Yoneshima, Minghui Sun, Jun Zhou, Qiuxia Wu, Meng Li
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT034.
https://doi.org/10.1158/1538-7445.AM2022-CT034
Published: 15 June 2022
View article titled, Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)
Journal Articles

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

Nicolas Girard, Jonathan Spicer, Mariano Provencio, Shun Lu, Stephen Broderick, Mark M. Awad, Tetsuya Mitsudomi, Keith Kerr, Julie Brahmer, Scott J. Swanson, Enriqueta Felip, Changli Wang, Gene B. Saylors, Ke-Neng Chen, Fumihiro Tanaka, Moishe Liberman, Cecile Dorange, Javed Mahmood, Junliang Cai, Patrick M. Forde
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT012.
https://doi.org/10.1158/1538-7445.AM2022-CT012
Published: 15 June 2022
View article titled, Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial
Journal Articles

Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation

Hong Jian, Zhenbo Song, Yiping Zhang, Kunyan Li, Nong Yang, Melissa Moore, Pingli Wang, Yanqiu Zhao, Yi Gong, Craig Underhill, Sang-We Kim, Cheng-Ta Yang, Ziyong Xiang, Zhe Shi, Ling Zhang, Yaolin Wang, Shun Lu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT505.
https://doi.org/10.1158/1538-7445.AM2022-CT505
Published: 15 June 2022
View article titled, Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRAS<sup>G12C</sup> mutation
Journal Articles

Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years

Shun Lu, Jie Wang, Yan Yu, Xinmin Yu, Yanping Hu, Zhiyong Ma, Xingya Li, Wu Zhuang, Yunpeng Liu, Weidong Li, Jiuwei Cui, Dong Wang, Wangjun Liao, Mengzhao Wang, Jianying Zhou, Zhehai Wang, Yuping Sun, Wanyu He, Yuanyuan Bao
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT552.
https://doi.org/10.1158/1538-7445.AM2022-CT552
Published: 15 June 2022
View article titled, Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years
Journal Articles

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Stephen Broderick, Julie Brahmer, Scott J. Swanson, Keith Kerr, Changli Wang, Gene B. Saylors, Fumihiro Tanaka, Hiroyuki Ito, Ke-Neng Chen, Cecile Dorange, Junliang Cai, Joseph Fiore, Nicholas Girard
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT003.
https://doi.org/10.1158/1538-7445.AM2021-CT003
Published: 01 July 2021
View article titled, Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial
Journal Articles

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Ying Cheng, Gang Wu, Peiguo Cao, Dongqing Lv, Xiangming Jin, Hong Jian, Chengshui Chen, Guanming Jiang, Panwen Tian, Kai Wang, Hui Zhao, Gongyan Chen, Qun Chen, Cuimin Ding, Junquan Yang, Renhua Guo, Guoping Sun, Bin Wang, Liyan Jiang, Wu Zhuang, Zhe Liu, Jian Fang, Yunpeng Liu, Jian Zhang, Jun Chen, Yueyin Pan, Qitao Yu, Min Zhao, Jiuwei Cui, Dianming Li, Tienan Yi, Zhuang Yu, Yan Yang, Yan Zhang, Xiuyi Zhi, Yunchao Huang, Rong Wu, Liangan Chen, Aimin Zang, Lejie Cao, Qingshan Li, Xiaoling Li, Yong Song, Donglin Wang, Shucai Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT170.
https://doi.org/10.1158/1538-7445.AM2021-CT170
Published: 01 July 2021
View article titled, Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
Journal Articles

Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14)

Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, Yulan Sun, Yuan Chen, Xingya Li, Hua Xu, Jianying Zhou, Liyan Jiang, Ying Cheng, Zhigang Han, Jianhua Shi, Gongyan Chen, Rui Ma, Yun Fan, Sanyuan Sun, Longxian Jiao, Xiaoyun Jia, Linfang Wang, Puhan Lu, Jing Li, Qian Xu, Xian Luo, Weiguo Su, Shun Lu
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT158.
https://doi.org/10.1158/1538-7445.AM2021-CT158
Published: 01 July 2021
View article titled, Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring <em>MET exon 14</em> skipping alterations (<em>METex14</em>)
Journal Articles

Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

D. Ross Camidge, Fedor Moiseenko, Irfan Cicin, Hidehito Horinouchi, Elena Filippova, Jair Bar, Shun Lu, Pascale Tomasini, Christopher Ocampo, Danielle Sullivan, David Maag, Jonathan W. Goldman
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT179.
https://doi.org/10.1158/1538-7445.AM2021-CT179
Published: 01 July 2021
View article titled, Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met<sup>+</sup> advanced non-small cell lung cancer